Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-17-005759
Filing Date
2017-01-26
Accepted
2017-01-26 17:36:47
Documents
2
Period of Report
2017-01-25

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1570
2 POA DOCUMENT poa.txt EX-24.3_696903 3906
  Complete submission text file 0001209191-17-005759.txt   6864
Mailing Address C/O COLLAGENEX PHARMACEUTICALS, INC. 41 UNIVERSITY DRIVE NEWTOWN PA 18940
Business Address
Powell Andrew Kenneth William (Reporting) CIK: 0001304113 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37581 | Film No.: 17550796

Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Issuer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations